Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster weight loss and diabetes drugs, though shares in the company were still up following positive Q1 results. Despite feeling the effects from the compounded glucagon-like peptide 1 receptor agonist (GLP-1RA) market, Novo Nordisk is still growing at a fast pace. Total revenues for the company came in at DKr78.1bn ($11.9bn) for Q1 2025, up 18% at constant exchange rates from the same period last year. Operating profit increased by 20%, reaching DKr38.8bn. Whilst the share price in the Copenhagen-listed company opened relatively unchanged to a pre-earnings release market close, the stock crept up 5.8% by mid-morning today (7 May). Novo Nordisk’s market cap of DKr1.56tn is the second largest in Europe. The Danish pharma company’s diabetes and obesity care business made up the bulk of total revenue. Sales for the unit, headed by GLP-1RA treatments Wegovy (semaglutide) and Ozempic (semaglutide) for weight loss and type 2 diabetes, respectively, reached DKr73.5bn. Novo Nordisk stated that obesity sales were the main driver – up 65% compared to Q1 2024. Diabetes sales were up a more modest 11%, with the market not as big as its burgeoning obesity counterpart. When it comes to its total 2025 outlook, Novo Nordisk does not think it will reach its previously anticipated target. The company cut its sales growth to a range of 13-21%, compared to earlier guidance of 16-24%. Operating profit growth is forecast at 16-24%, also down from a previous range of 19-27%, the company said. The reason, Novo Nordisk stated, was “lower-than-planned penetration of branded GLP-1RA treatments in the US, impacted by compounded GLP-1RAs”. Compounding pharmacies were allowed to produce vast quantities of semaglutide copies when Novo Nordisk’s branded drugs were in short supply starting in early 2022. Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide, under a prescription. Several telehealth companies such as Mochi Health and Hims & Hers began to offer compounded semaglutide during the shortage, significantly growing their customer base in this time. Their growth in popularity has meant an erosion of market share in the obesity sector for Novo Nordisk. The Danish company has now formed a partnership to provide Him & Hers customers access to the NovoCare Pharmacy. Novo Nordsik’s CEO Lars Fruergaard Jørgensen said: "In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US.” Story Continues Semaglutide is no longer in short supply, meaning the US Food and Drug Administration (FDA) has set deadlines for pharmacies to halt production of their copies. The share price increase today possibly reflected the easing of compounding pressures in 2025, along with a strong Q1. Some vendors, specifically online platforms, have said, however, that they will continue to offer compounded semaglutide as part of a personalised therapy plan. Separately, there are also sellers of illegal GLP-1RAs that are neither compounded nor FDA-approved. “We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1RA treatments,” Jørgensen added. Despite a temporary slowing in growth due to compounding pressures, GlobalData still forecasts peak sales of $26bn for Wegovy by 2031. GlobalData is the parent company of Pharmaceutical Technology. "Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...